Regional XXXX --assessment of tolerance to treatment.

@entity1 @entity5 @entity16 @entity591 @entity2837 @entity148 @entity221
To assess the @entity1 's tolerance and the complications of treatment associated with delivery of regional @entity221 using APAS BSD equipment, the data on 30 @entity1 who received regional @entity221 at the Radiation Oncology Center, Washington University School of @entity2837 , St. Louis, Missouri, has been reviewed. Most @entity1 presented with advanced or recurrent @entity5 not amenable to conventional treatment modalities. @entity221 was administered in combination with either radiotherapy or chemotherapy. Cardiovascular evaluation was a standard part of pre-treatment work-up. Temperatures were obtained through interstitial probes, catheters inserted into the body cavities and (to record core temperature) esophagus. Local discomfort, @entity148 , systemic temperature elevation, and @entity591 were the predominant factors limiting the number of sessions, the duration of sessions and the deposition of power, in 18, 6, 3, and 2 @entity1 , respectively. The complications of treatment were rare. Significant injuries of the superficial tissues were recorded in two @entity1 in whom this could be attributed to contact of urine and stool with the skin surface. @entity16 was observed in two @entity1 , both of whom had pelvic masses adjacent to or invading into the affected nerves. Both @entity1 had received pelvic irradiation. @entity16 developed within several days after the first @entity221 session and proved reversible within several months. No injuries of the visceral organs that could be clearly attributed to @entity221 have been recorded.
